Organisation: Seagen

IAM’s Market Makers of 2023

Via Licensing Alliance’s Heath Hoglund takes the top spot in our annual ranking of the patent market’s most innovative and influential deal makers and decision takers

14 March 2024

Patent cliff concerns drive Merck’s $11 billion Prometheus buyout

Deal hoped to stave off investor concerns about expiring patents and diversify product pipeline

20 April 2023

Market Makers top 20; Immersion Corp assertions; InterDigital v Lenovo FRAND decision; SVB collapse; pharma patent debate; plus much more

Get ready for the new working week with a summary of all the stories posted on the IAM platform over the past seven days

19 March 2023

Five patent takeaways from Pfizer’s $43 billion Seagen buyout

The takeover of the biopharma innovator is the largest pharma sector deal since 2019

14 March 2023

Top patentee jury verdicts from US courts in the third quarter

Here’s a look at the data about the rights’ holders and dollar sums behind the 31 patent damages awards from 1 July to 30 September

17 October 2022

Discretionary denials impact US life sciences IP strategies, but not as much as might be thought

SCOTUS refuses to consider NHK-Fintiv legal challenges, with significant implications for PTAB actions

20 January 2022

Legal challenges to the PTAB’s NHK-Fintiv discretionary denial regime mount

Life sciences companies are among those leading the way in going to court to get the current rules struck down

20 August 2021